ASV P\u0101rtikas un z\u0101\u013cu p\u0101rvalde (FDA) ir apstiprin\u0101jusi b\u016btisku atjaunin\u0101jumu popul\u0101r\u0101s kontracepcijas injekcijas “Depo-Provera”, ko ra\u017eo “Pfizer”, mar\u0137\u0113jum\u0101. Dokument\u0101 iek\u013cauts br\u012bdin\u0101jums par z\u0101\u013cu iesp\u0113jamo saist\u012bbu ar meningiomu (smadze\u0146u audz\u0113ju) att\u012bst\u012bbu.<\/p>\n
“Newsweek” zi\u0146o, ka l\u0113mums pie\u0146emts laik\u0101, kad sievietes ir iesniegu\u0161as gandr\u012bz 2000 pras\u012bbu ties\u0101, apgalvojot, ka p\u0113c ilgsto\u0161as \u200b\u200b”Depo-Provera” lieto\u0161anas vi\u0146\u0101m att\u012bst\u012bju\u0161ies smadze\u0146u audz\u0113ji. Meningiomas veidojas membr\u0101n\u0101s, kas p\u0101rkl\u0101j smadzenes un muguras smadzenes; liel\u0101k\u0101 da\u013ca ir labdab\u012bgas, bet aptuveni 20% var augt agres\u012bvi, un l\u012bdz pat 3% var b\u016bt \u013caundab\u012bgas.<\/p>\n
Kas ir main\u012bjies?<\/p>\n
S\u0101kot ar 12. decembri, P\u0101rtikas un z\u0101\u013cu p\u0101rvalde (FDA) pieprasa, lai br\u012bdin\u0101jumos un piesardz\u012bbas pas\u0101kumos tiktu iek\u013cauta inform\u0101cija par meningiom\u0101m, par kur\u0101m zi\u0146ots, atk\u0101rtoti un ilgsto\u0161i lietojot medroksiprogesterona acet\u0101tu, kas ir z\u0101\u013cu akt\u012bv\u0101 viela. Pacientiem ieteicams p\u0101rtraukt “Depo-Provera” lieto\u0161anu, ja tiek diagnostic\u0113ts audz\u0113js.<\/p>\n
“Pfizer” nost\u0101ja<\/p>\n
“Pfizer” pazi\u0146oja, ka pacientu dro\u0161\u012bba joproj\u0101m ir uz\u0146\u0113muma priorit\u0101te un atjaunin\u0101tais mar\u0137\u0113jums atspogu\u013co P\u0101rtikas un z\u0101\u013cu p\u0101rvaldes (FDA) l\u0113mumu. Ra\u017eot\u0101js uzsver, ka z\u0101les ir lietoju\u0161as miljoniem sievie\u0161u vis\u0101 pasaul\u0113 un t\u0101s joproj\u0101m ir svar\u012bga kontracepcijas<\/a> metode.<\/p>\n Cik popul\u0101ras ir \u0161\u012bs z\u0101les?<\/p>\n Saska\u0146\u0101 ar Slim\u012bbu kontroles un profilakses centru (CDC) datiem, viena no \u010detr\u0101m sieviet\u0113m ASV ir lietojusi “Depo-Provera” vismaz vienu reizi. Gandr\u012bz puse lietot\u0101ju p\u0101rtrauca lieto\u0161anu neapmierin\u0101t\u012bbas d\u0113\u013c, bet 74% – blakuspar\u0101d\u012bbu d\u0113\u013c.<\/p>\n Kas j\u0101zina pacientiem<\/p>\n \u0100rsti iesaka piev\u0113rst uzman\u012bbu t\u0101diem simptomiem k\u0101 past\u0101v\u012bgas galvass\u0101pes, neskaidra redze, krampji vai citi neirolo\u0123iski trauc\u0113jumi un nekav\u0113joties mekl\u0113t medic\u012bnisko pal\u012bdz\u012bbu. Sieviet\u0113m, kuras uztraucas par riskiem, ieteicams apspriest alternat\u012bvas kontracepcijas metodes ar savu \u0101rstu.<\/p>\n \t\t\t\t\t\tinfo<\/p>\n Uzzini pirmais
kas interesants noticis Latvij\u0101 un pasaul\u0113,
pievienojoties mums Telegram<\/a> vai Whatsapp<\/a> kan\u0101l\u0101<\/p>\n","protected":false},"excerpt":{"rendered":"ASV P\u0101rtikas un z\u0101\u013cu p\u0101rvalde (FDA) ir apstiprin\u0101jusi b\u016btisku atjaunin\u0101jumu popul\u0101r\u0101s kontracepcijas injekcijas “Depo-Provera”, ko ra\u017eo “Pfizer”, mar\u0137\u0113jum\u0101.…\n","protected":false},"author":2,"featured_media":106556,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[23,28,29,32,33,22,30,31,35,39,38,36,37,34,40,20,26,27,24,25,21],"class_list":{"0":"post-106555","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-aktualitates","8":"tag-aktualitates","9":"tag-breaking-news","10":"tag-breakingnews","11":"tag-featured-news","12":"tag-featurednews","13":"tag-headlines","14":"tag-latest-news","15":"tag-latestnews","16":"tag-latvia","17":"tag-latvian","18":"tag-latviesu","19":"tag-latviesu-valoda","20":"tag-latviesuvaloda","21":"tag-latvija","22":"tag-lv","23":"tag-news","24":"tag-popularakas-zinas","25":"tag-popularakaszinas","26":"tag-top-stories","27":"tag-topstories","28":"tag-zinas"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lv\/115905406105961670","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/106555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=106555"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/106555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/106556"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=106555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=106555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=106555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}